Abstracts tagged "Kidney"

Abstract Number: 1781 • 2014 ACR/ARHP Annual Meeting
Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years
Rennie L. Rhee¹, Susan L Hogan², Caroline J. Poulton², Julie Anne G. McGregor², J. Richard Landis³, Ronald Falk⁴ and Peter A. Merkel⁵, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²UNC Kidney Center, Chapel Hill, NC, ³Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, ⁴Dept of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, NC, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose Significant advances have been made in the diagnosis and treatment of patients with ANCA-associated vasculitis (AAV). However, little is known about how these advances…
Abstract Number: 1615 • 2014 ACR/ARHP Annual Meeting
MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE
Bo Qu^1,2, Xiao Han² and Nan Shen^1,2,3, ¹Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China, ²Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, Shanghai, China, ³The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH
Background/Purpose Type I interferon(IFN) is a critical pathogenic factor in Systemic Lupus Erythematosus(SLE) and its associated nephritis, as elevated IFN inducible genes have been found…
Abstract Number: 1235 • 2014 ACR/ARHP Annual Meeting
Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease
Takako Saeki¹, Mitsuhiro Kawano², Ichiro Mizushima², Motohisa Yamamoto³, Yoshifumi Ubara⁴, Hitoshi Nakashima⁵, Yoko Wada⁶, Tomoyuki Ito⁷, Hajime Yamazaki⁷, Ichiei Narita⁶ and Takao Saito^5,8, ¹Department of Internal Medicine, Nagaoka Red Cross Hospital, Nagaoka, Japan, ²Kanazawa University Hospital, Kanazawa, Japan, ³Sapporo Medical University School of Medicine, Sapporo, Japan, ⁴Toranomon Hospital, Tokyo, Japan, ⁵Div of Nephrol & Rheumatol, Dept of Int Med, Faculty of Medicine, Fukuoka University, Fukuoka, Japan, ⁶Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, ⁷Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁸General Medical Research Center, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Background/Purpose: In our earlier study of IgG4-related kidney disease (IgG4-RKD), we found that renal dysfunction, which was mostly attributable to IgG4-related tubulointerstitial nephritis, was significantly…
Abstract Number: 1032 • 2014 ACR/ARHP Annual Meeting
Neutralization of IL-17 Ameliorated Kidney Pathology Associated with Immune-Complex Mediated Autoimmune Glomerulonephritis
Partha Biswas¹, Kritika Ramani², Kelly Maers³, Anna Huppler⁴ and Sarah L. Gaffen⁵, ¹Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ²Dept of Medicine, University of Pittsburgh, Pittsburgh, PA, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsurgh, PA, ⁵Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Immune complex mediated autoimmune glomerulonephritis (AGN) is an often-fatal clinical manifestation of systemic lupus erythematosus. In recent years, pro-inflammatory cytokines in the nephritic kidney…
Abstract Number: 899 • 2014 ACR/ARHP Annual Meeting
Insurance Status and U.S. Region Associated with Placement of Permanent Vascular Access in Dialysis Patients with End-Stage Renal Disease Secondary to Lupus Nephritis
Laura Plantinga¹, Cristina M. Drenkard², Rachel Patzer³, William McClellan¹, Stephen Pastan⁴ and S. Sam Lim⁵, ¹Department of Epidemiology, Emory University, Atlanta, GA, ²Medicine, Div Rheumatology, Emory University, Atlanta, GA, ³Department of Surgery, Emory University, Atlanta, GA, ⁴Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Prior data suggest sociodemographic and regional variability in various indicators of quality of end-stage renal disease (ESRD) care, both overall and in the SLE…
Abstract Number: 459 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis
J. Kremer¹, A.J. Kivitz², J.a. Simon Campos³, E.L. Nasonov⁴, H. Tony⁵, B. Vlahos⁶, C. Hammond⁶, J. Bukowski⁶, H. Li⁶, S. Schulman⁶, S. Raber⁷, A. Zuckerman⁸ and J. Isaacs⁹, ¹Albany Medical College and The Center for Rheumatology, Albany, NY, ²Altoona Center for Clinical Research, Duncansville, PA, ³Hospital CEM/BIOCEM, Merida, Mexico, ⁴Nasonova State Institute of Rheumatology, Moscow, Russia, ⁵University Hospital Würzburg, Würzburg, Germany, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, San Diego, CA, ⁸Pfizer Inc, Groton, CT, ⁹National Institute for Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom
Background/Purpose: In the clinical development program of the oral Janus kinase inhibitor tofacitinib for the treatment of rheumatoid arthritis (RA), small mean increases in serum…
Abstract Number: 241 • 2014 ACR/ARHP Annual Meeting
Reduced Estimated Glomerular Filtration Rate Was Improved after Cessation of NSAID and Switching to Tramadol Hydrochloride/Acetaminophen Tablets (Ultracet^TM) in Patients with Chronic Musculoskeletal Pain
Kenji Miki^1,2,3,4, Hiroshi Kajiyama⁵, Kenrin Shi^2,6,7, Shigeshi Mori¹, Masao Yukioka⁸ and Masao Akagi¹, ¹Department of Orthopaedic Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Japan, ²Center for Pain Management, Osaka University Hospital, Suita, Japan, ³Dept. of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁴Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁵Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, ⁶Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ⁷Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Suita, Japan, ⁸Department of Rheumatology, Yukioka Hospital, Osaka, Japan
Background/Purpose: NSAID is widely used in patients with chronic musculoskeletal pain, but often deteriorates renal function with acute decline of estimated glomerular filtration rate (eGFR).…
Abstract Number: 9 • 2014 ACR/ARHP Annual Meeting
A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation
Vinicius Domingues¹, Darshana Dadhania², Choli Hartono², Raymond Pastore³ and Doruk Erkan⁴, ¹1320 York Avenue 17n, New York Presbyterian Hospital, New York, NY, ²Nephrology and Hypertension, New York Presbyterian Hospital, new york, NY, ³Hematology and Oncology, New York Presbyterian Hospital, new york, NY, ⁴Rheumatology, Hospital for Special Surgery; Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Antiphospholipid antibody (aPL) positive patients undergoing kidney transplantation (Tx) are at increased risk for perioperative complications. The objective of this study was to analyze…
Abstract Number: 2963 • 2014 ACR/ARHP Annual Meeting
The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia
Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Gout results from chronic hyperuricemia. Most gout patients exhibit an increased renal reabsorption of uric acid which leads to elevated levels of serum uric…
Abstract Number: 2603 • 2014 ACR/ARHP Annual Meeting
Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study
Anuj Shukla¹, Mohit kumar Rai¹, Narayan Prasad² and Vikas Agarwal¹, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Nephrology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose NSAIDs are the first-line therapy for spondyloarthritis (SpA) patients and are associated with the risk of kidney injury. Long-term NSAID use is known to…
Abstract Number: 2174 • 2013 ACR/ARHP Annual Meeting
Urinalysis Monitoring In Children With Henoch-Schönlein Purpura: Is It Time To Revise?
Hao Wang¹, Manasita Tanya², Justin Hung Tiong Tan², Sook Fun Hoh³, Lena Das⁴ and Thaschawee Arkachaisri⁵, ¹Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ²Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Pediatric Rheumatology, KK Women's and Children's Hospital, Singapore, Singapore, ⁵Rheumatology & Immunology, KK Women's and Children's Hospital and Duke-NUS Graduate Medical School, Singapore, Singapore
Background/Purpose: Major complication of Henoch-Schönlein Purpura (HSP) is renal impairment. Recommended urinalysis (UA) monitoring over a period of 2 years has been a common practice…
Abstract Number: 1175 • 2013 ACR/ARHP Annual Meeting
ABCG2 May Influence Risk Of Gout Through Extra-Renal Metabolic Pathways: Analysis Of The Effects Of The Q141K Variant On Serum Urate Responses To a Fructose Load
Nicola Dalbeth¹, Meaghan House², Gregory Gamble², Bregina Pool¹, Anne Horne², Lauren Purvis², Angela Stewart², Marilyn E. Merriman³, Murray Cadzow⁴, Amanda Phipps-Green³ and Tony R. Merriman³, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³Department of Biochemistry, University of Otago, Dunedin, New Zealand, ⁴University of Otago, Dunedin, New Zealand
Background/Purpose: Genetic variation in ABCG2 is a major risk factor for hyperuricemia and gout. This gene encodes a high-capacity urate transporter expressed in the intestine,…
Abstract Number: 888 • 2013 ACR/ARHP Annual Meeting
Role of Calcium/Calmodulin Kinase IV On Podocyte Function in Lupus Nephritis
Kunihiro Ichinose¹, Takeshi Ushigusa², Tomohiro Koga³, George C. Tsokos⁴ and Atsushi Kawakami⁵, ¹Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁵Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Role of calcium/calmodulin kinase IV on podocyte function in lupus nephritis Background/Purpose: Kidney podocytes and their slit diaphragms settle the integrity of renal basement membrane…
Abstract Number: 889 • 2013 ACR/ARHP Annual Meeting
Podocytes Take Up Adsdna Autoantibody Complexes
Anja Hillmann¹, Elisabeth Jung², Annika Engbers¹, Hedda Wardemann³, Annett M. Jacobi² and Thomas Pap⁴, ¹Institute of Experimental Musculoskeletal Medicine, University Hospital Münster, Münster, Germany, ²Rheumatology Internal Medicine D, University Hospital Münster, Münster, Germany, ³Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁴Institute of Experimental Muskuloskeletal Medicine, University Hospital Münster, Münster, Germany
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease, resulting in inflammation and tissue damage in several organs. This autoimmune reaction is caused by autoantibodies,…
Abstract Number: 645 • 2013 ACR/ARHP Annual Meeting
Transcript Profiling Of Blood and Kidney Biopsies From Chinese Patients With Lupus Nephritis Reveals Concordant Activation Of Type I IFN Signaling In The Blood and Kidney, Reduced B Cell Presence In The Blood, and Increased Macrophages In The Kidney
Zheng Liu¹, Chris, A. Morehouse¹, Xinfang Huang², Philip Brohawn¹, Nan Shen², Yihong Yao¹ and Brandon W. Higgs¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Dept of Rheumatology, Shanghai Ren Ji Hospital, Shanghai, China
Background/Purpose: Up-regulated expression of type I interferon-regulated genes has consistently been observed within the peripheral blood in a large proportion of patients with active systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].